Search

Your search keyword '"Lodge MA"' showing total 102 results

Search Constraints

Start Over You searched for: Author "Lodge MA" Remove constraint Author: "Lodge MA"
102 results on '"Lodge MA"'

Search Results

1. Abstracts of original contributions ASNC 2004 9th annual scientific session September 3-–October 3, 2004 New York, New York

3. Comparison of Multiple Segmentation Methods for Volumetric Delineation of Primary Prostate Cancer with Prostate-Specific Membrane Antigen-Targeted 18 F-DCFPyL PET/CT.

4. [ 18 F]FNDP PET neuroimaging test-retest repeatability and whole-body dosimetry in humans.

5. Test-retest repeatability of organ uptake on PSMA-targeted 18 F-DCFPyL PET/CT in patients with prostate cancer.

6. First-in-human imaging using [ 11 C]MDTC: a radiotracer targeting the cannabinoid receptor type 2.

7. Lack of repeatability of radiomic features derived from PET scans: Results from a 18 F-DCFPyL test-retest cohort.

8. Dynamic 18 F-Pretomanid PET imaging in animal models of TB meningitis and human studies.

9. High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with 18 F-DCFPyL.

10. Dynamic PET-facilitated modeling and high-dose rifampin regimens for Staphylococcus aureus orthopedic implant-associated infections.

11. Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of 68 Ga DOTATOC as Assessed by Dynamic Whole-body PET in Patients with Neuroendocrine Tumors: Implications for Diagnosis and Therapy.

12. Measurement of PET Quantitative Bias In Vivo.

13. Effect of Point-Spread Function Reconstruction for Indeterminate PSMA-RADS-3A Lesions on PSMA-Targeted PET Imaging of Men with Prostate Cancer.

15. Human Radiation Dosimetry for Orally and Intravenously Administered 18 F-FDG.

16. Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions.

17. The QIBA Profile for FDG PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy.

18. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [ 18 F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake.

20. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [ 18 F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake.

21. Imager-4D: New Software for Viewing Dynamic PET Scans and Extracting Radiomic Parameters from PET Data.

22. The Unique Role of Fluorodeoxyglucose-PET in Radioembolization.

23. Impact of Tumor Burden on Quantitative [ 68 Ga] DOTATOC Biodistribution.

24. Comparison of two software systems for quantification of myocardial blood flow in patients with hypertrophic cardiomyopathy.

25. Correction to: Comparison of two software systems for quantification of myocardial blood flow in patients with hypertrophic cardiomyopathy.

26. Novel Functional Renal PET Imaging With 18F-FDS in Human Subjects.

27. Dynamic whole-body PET imaging: principles, potentials and applications.

29. Noninvasive 11 C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis.

30. Measuring PET Spatial Resolution Using a Cylinder Phantom Positioned at an Oblique Angle.

31. Biodistribution and Radiation Dosimetry of 124 I-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation.

32. Feasibility of state of the art PET/CT systems performance harmonisation.

33. Combined model-based and patient-specific dosimetry for 18 F-DCFPyL, a PSMA-targeted PET agent.

34. Quantitative PET/CT in clinical practice: assessing the agreement of PET tumor indices using different clinical reading platforms.

35. Measuring temporal stability of positron emission tomography standardized uptake value bias using long-lived sources in a multicenter network.

36. ACR-SPR-STR Practice Parameter for the Performance of Cardiac Positron Emission Tomography - Computed Tomography (PET/CT) Imaging.

37. A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC.

38. Impact of PET/CT system, reconstruction protocol, data analysis method, and repositioning on PET/CT precision: An experimental evaluation using an oncology and brain phantom.

39. Enhancing ejection fraction measurement through 4D respiratory motion compensation in cardiac PET imaging.

40. Semiquantitative Parameters in PSMA-Targeted PET Imaging with 18 F-DCFPyL: Variability in Normal-Organ Uptake.

41. Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.

42. Simplifying volumes-of-interest (VOIs) definition in quantitative SPECT: Beyond manual definition of 3D whole-organ VOIs.

43. The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study.

44. Repeatability of SUV in Oncologic 18 F-FDG PET.

45. Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.

46. Repeatability of 18 F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma.

47. Comparison of quantitative Y-90 SPECT and non-time-of-flight PET imaging in post-therapy radioembolization of liver cancer.

48. Whole-body direct 4D parametric PET imaging employing nested generalized Patlak expectation-maximization reconstruction.

49. Practical PERCIST: A Simplified Guide to PET Response Criteria in Solid Tumors 1.0.

50. Impact of point spread function reconstruction on quantitative 18F-FDG-PET/CT imaging parameters and inter-reader reproducibility in solid tumors.

Catalog

Books, media, physical & digital resources